Evidence That HDAC7 Acts As an Epigenetic "reader" of AR Acetylation Through NCoR-HDAC3 Dissociation
Overview
Affiliations
Histone deacetylase (HDAC) proteins are epigenetic regulators that govern a wide variety of cellular events. With a role in cancer formation, HDAC inhibitors have emerged as anti-cancer therapeutics. Among the eleven metal-dependent class I, II, and IV HDAC proteins targeted by inhibitor drugs, class IIa HDAC4, -5, -7, and -9 harbor low deacetylase activity and are hypothesized to be "reader" proteins, which bind to post-translationally acetylated lysine. However, evidence linking acetyllysine binding to a downstream functional event is lacking. Here, we report for the first time that HDAC4, -5, and -7 dissociated from corepressor NCoR in the presence of an acetyllysine-containing peptide, consistent with reader function. Documenting the biological consequences of this possible reader function, mutation of a critical acetylation site regulated androgen receptor (AR) transcriptional activation function through HDAC7-NCoR-HDAC3 dissociation. The data document the first evidence consistent with epigenetic-reader functions of class IIa HDAC proteins.
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.
Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.
PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.
Slow-Binding and Covalent HDAC Inhibition: A New Paradigm?.
Raouf Y, Moreno-Yruela C JACS Au. 2024; 4(11):4148-4161.
PMID: 39610753 PMC: 11600154. DOI: 10.1021/jacsau.4c00828.
HDAC7 promotes ovarian cancer malignancy via AKT/mTOR signalling pathway.
Feng Q, Hao S, Liu X, Yan Z, Sheng K, Li Y J Cell Mol Med. 2024; 28(20):e70120.
PMID: 39431349 PMC: 11491867. DOI: 10.1111/jcmm.70120.
Kadier K, Niu T, Ding B, Chen B, Qi X, Chen D Adv Sci (Weinh). 2024; 11(36):e2309459.
PMID: 39049738 PMC: 11423193. DOI: 10.1002/advs.202309459.
Hansen T, Dankova D, Baek M, Grlas L, Olsen C JACS Au. 2024; 4(5):1854-1862.
PMID: 38818074 PMC: 11134391. DOI: 10.1021/jacsau.4c00042.